Navigation Links
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Date:3/12/2009

data evaluating the safety and performance of a bioabsorbable drug eluting coronary stent out to two years. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable device is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott has consistently been at the forefront of advances in interventional cardiology - from the early days of angioplasty to our continued success with bare metal stents and the market-leading XIENCE V drug eluting stent. Our bioabsorbable device is another example of scientific innovation leading to an interventional breakthrough," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Today's data publication in The Lancet confirms the promise our bioabsorbable device holds as a vasorestorative therapy for patients with coronary artery disease."

Abbott will begin enrolling patients in the second phase of its international ABSORB clinical trial in the first half of 2009.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days, six, nine and 18 months, and one and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the sten
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
4. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
8. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
9. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX,Pharmaceuticals, Inc. (NASDAQ:EPIX) ... executive officer of EPIX, is,scheduled to present at ... Tuesday, July 10, 2007 at 1:30 p.m.,(EDT) at ... The presentation will be webcast live and can ...
... DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.,(NASDAQ:ACCL), the ... announced today that its CFO,Rick Russo, will present ... in New York on July 11, 2007 at,10:30 ... the Mandarin,Oriental Hotel July 10th-12th. In attendance will ...
Cached Medicine Technology:EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference 2Accelrys to Present to Investors at C.E. Unterberg Emerging Growth,Opportunities Conference 2
(Date:4/23/2014)... A novel compound that targets an important brain receptor ... addiction behaviors, including relapse behavior, a University at Buffalo ... evidence that this may be a novel lead compound ... exist., The UB research was published as an online ... In the study, the compound, RO5263397, severely blunted a ...
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... be common in tropical countries along with the ... researchers in Houston, Texas whose study was published in ... available online. ,Staphylococcus aureus, or staph, ... in the nose of a quarter to a third ...
... the caregiver to a 12-year-old autistic boy who fell to ... being charged with the boy's// death. This despite the police ... his death. ,The boy's name has never been ... not say if they were reopening the case or what ...
... potent herbs, has now uncorked a new product: herbal wine. ... Thapa, a resident of tourist town Pokhara in western Nepal, ... ,For many families, alcohol is an integral part of ... local liquors thrive in Nepal's markets along with foreign beers, ...
... between overweight and infertility in women is well known, but ... the case of obese men.//, ,New research has ... that a man’s chances of getting infertile are enhanced by ... during the four years prior to participating in the study ...
... develop symptoms like chest pain or breathlessness almost 2 hours ... death victims were already at a risk as they had ... prevent sudden cardiac death can be made by learning to ... ,"Our study suggests that shifting the focus to educating ...
... often than biologists once thought. Cutting and rearrangement of the ... by// the human cells. ,The immune system of ... could also help researchers understand better how the immune system ... ,Depending on the specific type of protein required, an ...
Cached Medicine News:Health News:MRSA Linked with Rise in Bacterial Infections 2Health News:Nepal Uncorks 'Herbal Wine' 2Health News:Symptoms develop long before the 'Sudden' Cardiac Death 2Health News:'Mix and match' of proteins may have a significant role in immunity 2
Micro suture forceps....
30 Degree angle....
Operating microscope with motorized zoom and variable focus up to 405 mm....
Advanced operating microscope with zoom and variable focus up to 500 mm....
Medicine Products: